Placebo News and Research

RSS

Alcohol reduces communication in areas of brain responsible for perceiving social cues

Alcohol intoxication reduces communication between two areas of the brain that work together to properly interpret and respond to social signals, according to researchers at the University of Illinois at Chicago College of Medicine.

30 Aug 2013

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease in patients with mild dyslipidemia.

30 Aug 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

Testosterone improves exercise capacity in men with COPD

A systematic review and meta-analysis confirms that testosterone therapy improves exercise capacity in men with chronic obstructive pulmonary disease.

28 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

FDA extends PDUFA goal date for Auxilium Pharmaceuticals' sBLA for XIAFLEX

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has notified the Company that it is extending the Prescription Drug User Fee Act goal date for the Company's supplemental biologics license application for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease from September 6, 2013 to December 6, 2013.

28 Aug 2013

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network, are published today in The Lancet Diabetes & Endocrinology.

28 Aug 2013

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

Today Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of psoriasis.

27 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Mount Sinai scientists receive NIH grant to study clinical benefit of IGF-1 in children with PMS

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health to study Insulin-Like Growth Factor-1, a promising treatment for a subtype of autism called Phelan McDermid Syndrome.

27 Aug 2013

Sangamo BioSciences signs definitive agreement to buy Ceregene

Sangamo BioSciences, Inc. announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

26 Aug 2013

Scientists receive NIH grant to study commercially-available drug for treatment of PMS

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health (NIH) to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for a subtype of autism called Phelan McDermid Syndrome (PMS).

26 Aug 2013

Aromatherapy, IV dextrose may relieve nausea and vomiting after surgery

Two simple, non-drug treatments-aromatherapy and intravenous administration of a simple sugar solution-may offer effective new approaches to relieving nausea and vomiting after surgery, report a pair of studies in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

22 Aug 2013

Appetite-Controlling Hormone Leaves Obese People Still Hungry

...

22 Aug 2013

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.

22 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

Assumption that uterine blood redistributed into maternal circulation after delivery challenged

In an examination comparing the effects of two drugs on blood pressure, pulse, heart rate and cardiac output in women having elective delivery by cesarean section, an old assumption that uterine blood is redistributed into the maternal circulation after delivery was challenged, according to a study in the September issue of Anesthesiology.

22 Aug 2013

Antipsychotic drug not effective in treating delirium in critically ill patients

Haloperidol, an antipsychotic drug used in many hospitals to treat delirium in critically ill patients, is no more effective than placebo in reducing the number of days that critically ill patients spend either delirious or in a coma, according to new research published in The Lancet Respiratory Medicine.

22 Aug 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Placebo News and Research

Alcohol reduces communication in areas of brain responsible for perceiving social cues

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Testosterone improves exercise capacity in men with COPD

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

FDA extends PDUFA goal date for Auxilium Pharmaceuticals' sBLA for XIAFLEX

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

FDA grants Priority Review designation to sNDA for Nexavar tablets

Mount Sinai scientists receive NIH grant to study clinical benefit of IGF-1 in children with PMS

Sangamo BioSciences signs definitive agreement to buy Ceregene

Scientists receive NIH grant to study commercially-available drug for treatment of PMS

Aromatherapy, IV dextrose may relieve nausea and vomiting after surgery

Appetite-Controlling Hormone Leaves Obese People Still Hungry

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Assumption that uterine blood redistributed into maternal circulation after delivery challenged

Antipsychotic drug not effective in treating delirium in critically ill patients

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News